Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News HUTCHMED (China) Limited HCM

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The...

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:HCM)

Fundamentals Snapshot (NDAQ:HCM)

Current News (NDAQ:HCM)

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

GlobeNewswire September 7, 2022

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

GlobeNewswire August 23, 2022

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

GlobeNewswire August 9, 2022

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

GlobeNewswire August 8, 2022

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

GlobeNewswire August 7, 2022

HUTCHMED Reports 2022 Interim Results and Provides Business Updates

GlobeNewswire August 1, 2022

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

GlobeNewswire August 1, 2022

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

GlobeNewswire July 15, 2022

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

GlobeNewswire July 12, 2022

Opinion & Analysis (NDAQ:HCM)

No current opinion is available.

Bullboard Posts (NDAQ:HCM)